145
Participants
Start Date
November 30, 2015
Primary Completion Date
August 31, 2017
Study Completion Date
August 31, 2017
Caplacizumab
"* First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
Placebo
"* First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~* Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~* Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
Investigator Site, Valhalla
Investigator Site, Rochester
Investigator Site, Pittsburgh
Investigator Site, Winston-Salem
Investigator Site, Chapel Hill
Investigator Site, Durham
Investigator Site, Greenville
Investigator Site, Charleston
Investigator Site, Atlanta
Investigator Site, Birmingham
Investigator Site, Columbus
Investigator SIte, Cleveland
Investigator Site, Rochester
Investigator Site, St Louis
Investigator Site, Oklahoma City
Investigator Site, Houston
Investigator Site, Salt Lake City
Investigator Site, Los Angeles
Investigator Site, Boston
Investigator Site, Brisbane
Investigator Site 1, Melbourne
Investigator Site 2, Melbourne
Investigator Site 3, Melbourne
Investigator Site 4, Melbourne
Investigator Site 5, Melbourne
Investigator Site, Perth
Investigator Site 1, Sydney
Investigator Site 2, Sydney
Investigator Site, Vienna
Investigator Site, Antwerp
Investigator Site, Brussels
Investigator Site, Haine-Saint-Paul
Investigator Site, La Louvière
Investigator Site, Leuven
Invesigator Site, Montreal
Investigator Site, London
Investigator Site, Toronto
Investigator Site, Brno
Investigator Site, Hradec Králové
Investigator Site, Olomouc
Investigator Site, Ostrava-Poruba
Investigator Site, Caen
Investigator Site, Lille
Investigator Site, Marseille
Investigator Site, Nantes
Investigator Site 1, Paris
Investigator Site 2, Paris
Investigator Site 3, Paris
Investigator Site 4, Paris
Investigator site 5, Paris
Investigator Site, Rouen
Investigator Site, Salouël
Investigator site, Cologne
Investigator site 1, Dresden
Investigator site 2, Dresden
Investigator site, Erlangen
Investigator site, Göppingen
Investigator site, Kiel
Investigator site, Leipzig
Investigator site, Würzburg
Investigator Site 1, Budapest
Investigator Site 2, Budapest
Investigator Site, Debrecen
Investigator Site 1, Be’er Ya‘aqov
Investigator Site 2, Be’er Ya‘aqov
Investigator Site, Haifa
Investigator Site 1, Jerusalem
Investigator Site 2, Jerusalem
Investigator Site, Nahariya
Investigator Site, Petah Tikva
Investigator Site, Tel Aviv
Investigator Site, Catania
Investigator Site 1, Milan
Investigator Site 2, Milan
Investigator Site, Pesaro
Investigator Site, Rome
Investigator Site, Vicenza
Investigator Site, Amersfoort
Investigator Site, Leiden
Investigator Site, Rotterdam
Investigator Site, Veldhoven
Investigator Site 1, Barcelona
Investigator Site 2, Barcelona
Investigator Site, Madrid
Investigator Site, Seville
Investigator Site 1, Valencia
Investigator Site 2, Valencia
Investigator site 3, Valencia
Investigator Site, Bern
Investigator Site, Zurich
Investigator Site, Ankara
Investigator Site 1, Denizli
Investigator Site 2, Denizli
Investigator site 3, Denizli
Investigator Site, Istanbul
Investigator Site, Kayseri
Investigator Site, Trabzon
Investigator Site, Bristol
Investigator Site, Liverpool
Investigator Site 1, London
Investigator Site 2, London
Ablynx, a Sanofi company
INDUSTRY